Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.
Sol-Gel Technologies, Ltd. acquired topically applied patidegib, a hedgehog-signaling pathway blocker for the treatment of Gorlin syndrome, from






